Cue Biopharma, Inc

(NASDAQ:CUE)

Latest On Cue Biopharma, Inc (CUE):

Date/Time Type Description Signal Details
2023-05-10 01:40 ESTNewsCue Biopharma GAAP EPS of -$0.29 in-line, revenue of $0.19M misses by $1.76MN/A
2023-03-22 09:56 ESTNewsCue Biopharma, Inc. (CUE) Q4 2022 Earnings Call TranscriptN/A
2023-03-21 18:42 ESTNewsCue Biopharma GAAP EPS of -$0.37 misses by $0.06, revenue of $0.15M beats by $0.05MN/A
2023-01-23 14:05 ESTNewsCue biopharma names Matteo Levisetti as new Chief Medical OfficerN/A
2022-11-15 00:39 ESTNewsCue Biopharma GAAP EPS of -$0.31 beats by $0.07, revenue of $0.07M misses by $0.37MN/A
2022-11-15 00:38 ESTNewsCue Biopharma, Inc. (CUE) Q3 2022 Earnings Call TranscriptN/A
2022-10-04 15:01 ESTNewsCue Biopharma shares rise ~10% on FDA fast track nod for head and neck cancer drugN/A
2022-08-25 11:05 ESTNewsCue Biopharma, Inc.'s (CUE) CEO Dan Passeri on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-24 02:39 ESTNewsCue Biopharma, Inc. (CUE) CEO Dan Passeri on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-05 01:24 ESTNewsCue Biopharma GAAP EPS of -$0.37N/A
2022-05-11 21:46 ESTNewsCue Biopharma IND application for cancer candidate CUE-102 accepted by FDAN/A
2022-05-11 21:46 ESTNewsCue Biopharma: A First AssessmentN/A
2022-05-11 02:18 ESTNewsCue Biopharma GAAP EPS of -$0.44 misses by $0.02, revenue of $1M misses by $1.92MN/A
2022-04-05 23:17 ESTNewsCue Biopharma extends gains on insider purchaseN/A
2022-02-24 10:56 ESTNewsCue Biopharma: Too Long To Arrive At Topline Trial DataN/A
2022-01-27 12:59 ESTNewsCue data on head and neck cancer candidate doesn't impress investors; shares down 26%N/A
2022-01-26 20:04 ESTNewsCue reports two objective responses in CUE-101 combo for head and neck cancerN/A
2022-01-05 19:32 ESTNewsCue Biopharma to get $3M from LG Chem as it reaches milestone in cancer drug programN/A
2021-11-15 23:19 ESTNewsCue Biopharma rises on data for CUE-101 in head and neck cancerN/A
2021-09-21 15:19 ESTNewsCue Bio secures news U.S. patents for CUE-101N/A
2021-08-18 07:31 ESTNewsCue Biopharma EPS beats by $0.05, beats on revenueN/A
2021-08-18 07:30 ESTNewsCue Biopharma, Inc. (CUE) CEO Dan Passeri on Q2 2021 Results - Earnings Call TranscriptN/A
2021-07-21 03:07 ESTNewsCue Biopharma doses the first patient in trial for CUE-101 in head and neck cancerN/A
2021-03-17 21:11 ESTNewsCue Biopharma, Inc. (CUE) CEO Daniel Passeri on Q4 2020 Results - Earnings Call TranscriptN/A
2021-03-17 21:11 ESTNewsCue Biopharma, Inc. 2021 Q4 - Results - Earnings Call PresentationN/A
2021-03-16 22:24 ESTNewsCue Biopharma EPS beats by $0.03, misses on revenueN/A
2021-03-10 11:21 ESTFinancialsCompany financials have been released.Neutral
2021-03-10 11:21 ESTEarnings EstimateAn EPS average of -$1.97 is estimated for the 2022 year.Sell
2021-03-10 11:21 ESTEarnings EstimateAn EPS average of -$0.40 is estimated for the quarter ending on June 30, 2021.Sell
2021-02-10 07:26 ESTAnalyst RatingThe Analyst Target Price has decreased from $31.17 to $30.Neutral
2021-01-08 00:54 ESTNewsCue Biopharma: CUE-101's Phase 1 Promising Progress, 1 New IND Expected, Funding Until Q2 2022N/A
2020-12-13 03:46 ESTFinancialsCompany financials have been released.Neutral
2020-11-25 11:44 ESTAnalyst RatingThe Analyst Target Price has increased from $30 to $31.17.Buy
2020-11-20 18:03 ESTNewsCue Biopharma (CUE) Investor Presentation - SlideshowN/A
2020-11-19 15:09 ESTNewsCue Biopharma reports Q3 results, issues update to lead programN/A
2020-11-19 11:42 ESTAnalyst RatingThe Analyst Target Price has decreased from $31 to $30.Neutral
2020-11-18 11:19 ESTNewsCue Biopharma EPS beats by $0.12, misses on revenueN/A
2020-11-11 11:31 ESTFinancialsCompany financials have been released.Neutral
2020-11-10 11:39 ESTEarnings EstimateAn EPS average of -$0.45 is estimated for the quarter ending on March 31, 2021.Sell
2020-11-07 15:32 ESTFinancialsCompany financials have been released.Neutral
2020-10-06 17:51 ESTInsider TradeAnish Suri has directly acquired 33,333 shares and currently holds 67,891 shares.Buy
2020-10-01 16:19 ESTInsider TradeCameron Gray has directly acquired 5,000 shares and currently holds 677,500 shares.Buy
2020-10-01 16:19 ESTInsider TradeCameron Gray has directly acquired 5,000 shares and currently holds 672,500 shares.Buy
2020-09-26 12:29 ESTFinancialsCompany financials have been released.Neutral
2020-09-17 04:37 ESTFinancialsCompany financials have been released.Neutral
2020-09-02 04:27 ESTAnalyst RatingThe Analyst Target Price has decreased from $31.8 to $31.Neutral
2020-09-01 05:39 ESTNewsCue Biopharma EPS beats by $0.05, misses on revenueN/A
2020-09-01 05:38 ESTNewsCue Biopharma, Inc. (CUE) CEO Dan Passeri on Q2 2020 Results - Earnings Call TranscriptN/A
2020-08-25 16:49 ESTInsider TradeKerri-Ann Millar has directly acquired 6,666 shares and currently holds 7,666 shares.Buy
2020-08-14 08:31 ESTFinancialsCompany financials have been released.Neutral

About Cue Biopharma, Inc (CUE):

Cue Biopharma, Inc., a biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate CUE-101, a protein biologic that is in Phase I clinical trials designed to target and activate antigen-specific T cells for human papilloma virus driven cancers. The company offers CUE-102, an onco-fetal viral antigen for cancers, including solid tumors and hematologic malignancies; CUE-103, an antigen; CUE-200 framework that includes CD80 and/or 4-1BBL to reactivate exhausted T cells and design to enhance antigen-specific T cell for the treatment of chronic infectious diseases; and CUE-300 framework to target various autoimmune diseases. It has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for Immuno-selective targeting and alteration of T cells (STAT) in the field of oncology; and Albert Einstein College of Medicine to develop Immuno-STAT biologics for chronic infectious diseases, as well as a strategic research collaboration with Dr. Michael Dustin and Oxford University. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

CUE Quotes by TradingView

See Advanced Chart

General

  • Name Cue Biopharma, Inc
  • Symbol CUE
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 50
  • Fiscal Year EndDecember
  • IPO Date2018-01-02
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.cuebiopharma.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 134.79
  • Price/Book (Most Recent Quarter) 5.72
  • Enterprise Value Revenue 118.46
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$1.52
  • Next Year EPS Estimate -$1.61
  • Next Quarter EPS Estimate -$0.40
  • Operating Margin -1428%
  • Return on Assets -33%
  • Return on Equity -67%
  • Revenue 3.15 million
  • Earnings Per Share -$2.20
  • Revenue Per Share $0.11
  • Gross Profit -30391380
  • Quarterly Earnings Growth -54.7%
View More

Highlights

  • Market Capitalization 408.74 million
  • EBITDA -43568648
  • PE Ratio -1.51
  • Analyst Target Price $30
  • Book Value Per Share $2.60
View More

Share Statistics

  • Shares Outstanding 30.46 million
  • Shares Float 22 million
  • % Held by Insiders 1076%
  • % Held by Institutions 65.25%
  • Shares Short 2.78 million
  • Shares Short Prior Month 2.76 million
  • Short Ratio 8.92
  • Short % of Float 9%
  • Short % of Shares Outstanding 9%
View More

Technicals

  • Beta 1.91
  • 52 Week High $31.69
  • 52 Week Low $10.75
  • 50 Day Moving Average 14.25
  • 200 Day Moving Average 14.04
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Cue Biopharma, Inc (CUE) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Cue Biopharma, Inc (CUE) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-09$475325-$0.36-$0.35-3.6%
2020-09-302020-11-09$N/A-$0.34-$0.3810.53%
2020-06-302020-08-10$N/A-$0.38-$0.4310.59%
2020-03-312020-05-07$900000-$0.48-$0.37-28.86%
2019-12-312020-03-12$1.05 million-$0.36-$0.4418.18%
2019-09-302019-11-07$984000-$0.31-$0.4429.55%
2019-06-302019-08-08$1.06 million-$0.46-$0.5617.86%
2019-03-312019-05-08$370000-$0.54-$0.40-35%
2018-12-312019-03-14$330604-$0.58-$0.40-45%
2018-09-302018-11-13$449000-$0.62-$0.38-63.16%
2018-06-302018-08-13$172000-$0.36
2018-03-312018-05-14$191000-$0.38

Cue Biopharma, Inc (CUE) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Cue Biopharma, Inc (CUE) Chart:

Cue Biopharma, Inc (CUE) News:

Below you will find a list of latest news for Cue Biopharma, Inc (CUE) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Cue Biopharma, Inc (CUE) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2024-05-1710.5CALL0 11002.95TRUE00
2024-05-1720.1CALL0 1080FALSE00
2024-05-1730.08CALL0 570FALSE00
2024-05-1740CALL0 00FALSE00
2024-05-1750CALL0 00FALSE00
2024-05-1710PUT0 00FALSE00
2024-05-1720.55PUT0 79137.84TRUE00
2024-05-1730PUT0 0266.01TRUE00
2024-05-1740PUT0 0245.71TRUE00
2024-05-1750PUT0 0520.25TRUE00
2024-06-2110CALL0 00TRUE00
2024-06-2120CALL0 00FALSE00
2024-06-2130CALL0 00FALSE00
2024-06-2140CALL0 00FALSE00
2024-06-2150CALL0 00FALSE00
2024-06-2110PUT0 00FALSE00
2024-06-2120PUT0 0124.48TRUE00
2024-06-2130PUT0 0666.49TRUE00
2024-06-2140PUT0 0126.21TRUE00
2024-06-2150PUT0 0179.98TRUE00
2024-07-1910.66CALL0 106343.3TRUE00
2024-07-1920.45CALL0 1360FALSE00
2024-07-1930.09CALL42 354117.56FALSE-0.01-0.1
2024-07-1940.1CALL0 2810FALSE00
2024-07-1950.1CALL0 1660FALSE00
2024-07-1960.05CALL3 5161.94FALSE0.050
2024-07-1910.05PUT0 100FALSE00
2024-07-1920.5PUT0 3496.94TRUE00
2024-07-1931.15PUT0 9125.01TRUE00
2024-07-1941.65PUT0 3158.16TRUE00
2024-07-1953.46PUT0 1257.36TRUE00
2024-07-1960PUT0 0310.42TRUE00
2024-10-1811.05CALL0 10TRUE00
2024-10-1820.33CALL0 220994.76FALSE00
2024-10-1831.3CALL0 283111.22FALSE00
2024-10-1840.15CALL0 20114.08FALSE00
2024-10-1850.2CALL0 690FALSE00
2024-10-1810.15PUT0 40109.49FALSE00
2024-10-1820.6PUT0 9105.86TRUE00
2024-10-1831.25PUT0 1131.95TRUE00
2024-10-1840PUT0 0146.53TRUE00
2024-10-1852.9PUT0 2259.16TRUE00

Latest CUE Trades:

Date Shares Price
Jun 13, 2022 7:58 PM EST100$3.16
Jun 13, 2022 7:58 PM EST100$3.16
Jun 13, 2022 7:59 PM EST10$3.155
Jun 13, 2022 7:59 PM EST50$3.155
Jun 13, 2022 7:59 PM EST31$3.16

Cue Biopharma, Inc (CUE) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1645460/000119312520180915/0001193125-20-180915-index.htm
2019-07-03UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1645460/000000000019010729/0000000000-19-010729-index.htm
2019-07-31UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1645460/000000000019011864/0000000000-19-011864-index.htm
2020-02-07SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1645460/000083423720008154/0000834237-20-008154-index.htm
2020-10-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000089924320026662/0000899243-20-026662-index.htm
2020-10-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000089924320027608/0000899243-20-027608-index.htm
2020-02-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1645460/000090266420001125/0000902664-20-001125-index.htm
2020-02-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1645460/000110465920021215/0001104659-20-021215-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1645460/000117494719000210/0001174947-19-000210-index.htm
2018-07-23424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1645460/000119312518223754/0001193125-18-223754-index.htm
2018-08-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1645460/000119312518238242/0001193125-18-238242-index.htm
2018-11-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1645460/000119312518321949/0001193125-18-321949-index.htm
2018-11-138-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1645460/000119312518325520/0001193125-18-325520-index.htm
2018-12-268-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1645460/000119312518358131/0001193125-18-358131-index.htm
2019-01-04S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1645460/000119312519002594/0001193125-19-002594-index.htm
2019-01-14S-3/ARegistration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1645460/000119312519009008/0001193125-19-009008-index.htm
2019-02-08424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1645460/000119312519032256/0001193125-19-032256-index.htm
2019-03-14S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1645460/000119312519074909/0001193125-19-074909-index.htm
2019-04-3010-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1645460/000119312519129372/0001193125-19-129372-index.htm
2019-05-30PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1645460/000119312519159883/0001193125-19-159883-index.htm
2019-06-05424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1645460/000119312519165605/0001193125-19-165605-index.htm
2019-06-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1645460/000119312519165608/0001193125-19-165608-index.htm
2019-06-18DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1645460/000119312519175745/0001193125-19-175745-index.htm
2019-06-18DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1645460/000119312519175750/0001193125-19-175750-index.htm
2019-07-0910-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1645460/000119312519191276/0001193125-19-191276-index.htm
2019-07-0910-Q/AQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1645460/000119312519191281/0001193125-19-191281-index.htm
2019-07-09CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1645460/000119312519191288/0001193125-19-191288-index.htm
2019-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1645460/000119312519214166/0001193125-19-214166-index.htm
2019-10-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1645460/000119312519263791/0001193125-19-263791-index.htm
2019-10-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1645460/000119312519265125/0001193125-19-265125-index.htm
2019-11-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1645460/000119312519289917/0001193125-19-289917-index.htm
2019-11-25424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1645460/000119312519300046/0001193125-19-300046-index.htm
2019-11-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1645460/000119312519300091/0001193125-19-300091-index.htm
2020-02-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1645460/000119312520029740/0001193125-20-029740-index.htm
2020-03-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1645460/000119312520058942/0001193125-20-058942-index.htm
2020-03-1210-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1645460/000119312520071718/0001193125-20-071718-index.htm
2020-03-12S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1645460/000119312520071746/0001193125-20-071746-index.htm
2020-03-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1645460/000119312520076018/0001193125-20-076018-index.htm
2020-03-27424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1645460/000119312520088881/0001193125-20-088881-index.htm
2020-03-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1645460/000119312520088890/0001193125-20-088890-index.htm
2020-04-2910-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1645460/000119312520126402/0001193125-20-126402-index.htm
2020-05-15PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1645460/000119312520143998/0001193125-20-143998-index.htm
2020-05-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1645460/000119312520146121/0001193125-20-146121-index.htm
2020-05-29DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1645460/000119312520155706/0001193125-20-155706-index.htm
2020-05-29DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1645460/000119312520155724/0001193125-20-155724-index.htm
2020-06-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1645460/000119312520162176/0001193125-20-162176-index.htm
2020-06-22S-3ASRAutomatic shelf registration statement of securities of well-known seasoned issuershttps://www.sec.gov/Archives/edgar/data/1645460/000119312520175657/0001193125-20-175657-index.htm
2020-06-22424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1645460/000119312520175737/0001193125-20-175737-index.htm
2020-06-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1645460/000119312520175747/0001193125-20-175747-index.htm
2020-06-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1645460/000119312520180915/0001193125-20-180915-index.htm
2020-07-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1645460/000119312520193348/0001193125-20-193348-index.htm
2020-08-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1645460/000119312520228378/0001193125-20-228378-index.htm
2020-09-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1645460/000119312520247622/0001193125-20-247622-index.htm
2018-07-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919118043905/0001209191-18-043905-index.htm
2018-07-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919118043906/0001209191-18-043906-index.htm
2018-07-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919118043907/0001209191-18-043907-index.htm
2018-08-023Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919118045012/0001209191-18-045012-index.htm
2018-08-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919118045015/0001209191-18-045015-index.htm
2018-08-023Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919118045020/0001209191-18-045020-index.htm
2018-08-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919118045024/0001209191-18-045024-index.htm
2018-08-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919118047026/0001209191-18-047026-index.htm
2018-08-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919118047605/0001209191-18-047605-index.htm
2018-08-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919118048862/0001209191-18-048862-index.htm
2018-12-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919118062294/0001209191-18-062294-index.htm
2018-12-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919118062473/0001209191-18-062473-index.htm
2018-12-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919118062856/0001209191-18-062856-index.htm
2018-12-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919118063198/0001209191-18-063198-index.htm
2018-12-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919118063385/0001209191-18-063385-index.htm
2018-12-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919118063658/0001209191-18-063658-index.htm
2018-12-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919118063800/0001209191-18-063800-index.htm
2018-12-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919118064085/0001209191-18-064085-index.htm
2018-12-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919118064086/0001209191-18-064086-index.htm
2018-12-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919118064128/0001209191-18-064128-index.htm
2018-12-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919118064186/0001209191-18-064186-index.htm
2018-12-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919118064233/0001209191-18-064233-index.htm
2019-01-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919119000261/0001209191-19-000261-index.htm
2019-01-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919119000270/0001209191-19-000270-index.htm
2019-01-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919119001321/0001209191-19-001321-index.htm
2019-01-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919119001324/0001209191-19-001324-index.htm
2019-01-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919119001326/0001209191-19-001326-index.htm
2019-01-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919119001328/0001209191-19-001328-index.htm
2019-01-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919119001330/0001209191-19-001330-index.htm
2019-01-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919119001332/0001209191-19-001332-index.htm
2019-01-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919119001333/0001209191-19-001333-index.htm
2019-01-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919119001336/0001209191-19-001336-index.htm
2019-01-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919119002244/0001209191-19-002244-index.htm
2019-01-155Annual statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919119003724/0001209191-19-003724-index.htm
2019-01-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919119005540/0001209191-19-005540-index.htm
2019-01-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919119005543/0001209191-19-005543-index.htm
2019-03-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919119018083/0001209191-19-018083-index.htm
2019-03-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919119018084/0001209191-19-018084-index.htm
2019-03-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919119018088/0001209191-19-018088-index.htm
2019-03-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919119018090/0001209191-19-018090-index.htm
2019-03-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919119018091/0001209191-19-018091-index.htm
2019-06-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919119035525/0001209191-19-035525-index.htm
2019-06-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919119035958/0001209191-19-035958-index.htm
2019-06-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919119038900/0001209191-19-038900-index.htm
2019-10-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919119052713/0001209191-19-052713-index.htm
2019-10-073Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919119052714/0001209191-19-052714-index.htm
2019-10-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919119052715/0001209191-19-052715-index.htm
2019-11-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919119054991/0001209191-19-054991-index.htm
2019-12-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919119061377/0001209191-19-061377-index.htm
2019-12-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919119062031/0001209191-19-062031-index.htm
2019-12-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919119062325/0001209191-19-062325-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919120002054/0001209191-20-002054-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919120002057/0001209191-20-002057-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919120002058/0001209191-20-002058-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919120002060/0001209191-20-002060-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919120002061/0001209191-20-002061-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919120002063/0001209191-20-002063-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919120002064/0001209191-20-002064-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919120002066/0001209191-20-002066-index.htm
2020-02-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919120008793/0001209191-20-008793-index.htm
2020-02-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919120008800/0001209191-20-008800-index.htm
2020-02-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919120008809/0001209191-20-008809-index.htm
2020-02-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919120008815/0001209191-20-008815-index.htm
2020-02-244/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919120012027/0001209191-20-012027-index.htm
2020-03-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919120021239/0001209191-20-021239-index.htm
2020-04-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919120024164/0001209191-20-024164-index.htm
2020-05-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919120028490/0001209191-20-028490-index.htm
2020-06-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919120038885/0001209191-20-038885-index.htm
2020-08-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919120045142/0001209191-20-045142-index.htm
2020-08-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919120045144/0001209191-20-045144-index.htm
2020-08-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919120045698/0001209191-20-045698-index.htm
2020-08-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919120045702/0001209191-20-045702-index.htm
2020-08-104/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919120045921/0001209191-20-045921-index.htm
2020-08-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919120048212/0001209191-20-048212-index.htm
2020-09-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919120051142/0001209191-20-051142-index.htm
2020-09-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1645460/000120919120051145/0001209191-20-051145-index.htm
2019-12-18SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1645460/000149315219019389/0001493152-19-019389-index.htm
2020-04-21SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1645460/000149315220006833/0001493152-20-006833-index.htm
2018-08-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1645460/000156459018021470/0001564590-18-021470-index.htm
2018-11-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1645460/000156459018029316/0001564590-18-029316-index.htm
2019-03-1410-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1645460/000156459019007832/0001564590-19-007832-index.htm
2019-05-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1645460/000156459019017298/0001564590-19-017298-index.htm
2019-08-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1645460/000156459019030813/0001564590-19-030813-index.htm
2019-11-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1645460/000156459019041703/0001564590-19-041703-index.htm
2020-03-1210-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1645460/000156459020010212/0001564590-20-010212-index.htm
2020-05-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1645460/000156459020022851/0001564590-20-022851-index.htm
2020-08-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1645460/000156459020038375/0001564590-20-038375-index.htm
2018-07-19EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1645460/999999999518001834/9999999995-18-001834-index.htm
2019-02-19CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1645460/999999999719000433/9999999997-19-000433-index.htm

Cue Biopharma, Inc (CUE) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Cue Biopharma, Inc (CUE). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 1076%
Institutional Ownership: 6525%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2019-12-31CHRISTOPHER A MARLETTDirectorSell9,000.0015.71141,390.000.00https://www.sec.gov/Archives/edgar/data/1645460/000120919119062325/0001209191-19-062325-index.htm
2018-08-29Kerri-Ann MillarVP-FinanceBuy1,000.008.488,480.001,000.00https://www.sec.gov/Archives/edgar/data/1645460/000120919118048862/0001209191-18-048862-index.htm
2018-12-17ANTHONY DIGIANDOMENICODirectorBuy10,000.005.4854,800.0010,000.00https://www.sec.gov/Archives/edgar/data/1645460/000120919118063198/0001209191-18-063198-index.htm
2018-12-12CHRISTOPHER A MARLETTDirectorBuy3,189.005.0716,168.2310,732.00https://www.sec.gov/Archives/edgar/data/1645460/000120919118062473/0001209191-18-062473-index.htm
2020-06-24Aaron G.L. FletcherDirectorBuy4,547.0024.64112,038.08155,499.00https://www.sec.gov/Archives/edgar/data/1645460/000120919120038885/0001209191-20-038885-index.htm
2020-06-24Aaron G.L. FletcherDirectorBuy2,953.0025.2474,533.72158,452.00https://www.sec.gov/Archives/edgar/data/1645460/000120919120038885/0001209191-20-038885-index.htm
2019-06-10Colin SandercockSVP, General Counsel and SecBuy14,938.007.93118,458.3416,938.00https://www.sec.gov/Archives/edgar/data/1645460/000120919119035958/0001209191-19-035958-index.htm
2020-08-03Colin SandercockSVP, General Counsel and SecSell6,425.0020.00128,500.0017,125.00https://www.sec.gov/Archives/edgar/data/1645460/000120919120045144/0001209191-20-045144-index.htm
2020-08-04Colin SandercockSVP, General Counsel and SecSell201.0020.054,030.0517,125.00https://www.sec.gov/Archives/edgar/data/1645460/000120919120045144/0001209191-20-045144-index.htm
2020-08-05Colin SandercockSVP, General Counsel and SecSell13,274.0020.00265,480.0017,125.00https://www.sec.gov/Archives/edgar/data/1645460/000120919120045702/0001209191-20-045702-index.htm
2020-08-04Colin SandercockSVP, General Counsel and SecBuy201.007.501,507.5017,326.00https://www.sec.gov/Archives/edgar/data/1645460/000120919120045144/0001209191-20-045144-index.htm
2018-12-21Anish SuriChief Scientific OfficerBuy2,000.004.378,740.002,000.00https://www.sec.gov/Archives/edgar/data/1645460/000120919118064128/0001209191-18-064128-index.htm
2019-06-06Colin SandercockSVP, General Counsel and SecBuy2,000.007.1014,200.002,000.00https://www.sec.gov/Archives/edgar/data/1645460/000120919119035958/0001209191-19-035958-index.htm
2018-12-21ANTHONY DIGIANDOMENICODirectorBuy10,000.004.4944,900.0020,000.00https://www.sec.gov/Archives/edgar/data/1645460/000120919118064085/0001209191-18-064085-index.htm
2018-12-13CHRISTOPHER A MARLETTDirectorBuy10,000.005.0650,600.0020,732.00https://www.sec.gov/Archives/edgar/data/1645460/000120919118062856/0001209191-18-062856-index.htm
2020-08-03Colin SandercockSVP, General Counsel and SecBuy6,425.007.5048,187.5023,550.00https://www.sec.gov/Archives/edgar/data/1645460/000120919120045144/0001209191-20-045144-index.htm
2018-12-18CHRISTOPHER A MARLETTDirectorBuy3,664.005.2019,052.8024,396.00https://www.sec.gov/Archives/edgar/data/1645460/000120919118063385/0001209191-18-063385-index.htm
2018-12-19CHRISTOPHER A MARLETTDirectorBuy400.005.002,000.0024,796.00https://www.sec.gov/Archives/edgar/data/1645460/000120919118063658/0001209191-18-063658-index.htm
2018-12-24ANTHONY DIGIANDOMENICODirectorBuy10,000.004.8148,100.0030,000.00https://www.sec.gov/Archives/edgar/data/1645460/000120919119002244/0001209191-19-002244-index.htm
2020-08-05Colin SandercockSVP, General Counsel and SecBuy13,274.007.5099,555.0030,399.00https://www.sec.gov/Archives/edgar/data/1645460/000120919120045702/0001209191-20-045702-index.htm
2018-12-20CHRISTOPHER A MARLETTDirectorBuy9,438.004.7444,736.1234,234.00https://www.sec.gov/Archives/edgar/data/1645460/000120919118063800/0001209191-18-063800-index.htm
2020-08-03Anish SuriPresident and CSOSell5,800.0020.01116,058.0034,558.00https://www.sec.gov/Archives/edgar/data/1645460/000120919120045142/0001209191-20-045142-index.htm
2020-08-04Anish SuriPresident and CSOSell400.0020.148,056.0034,558.00https://www.sec.gov/Archives/edgar/data/1645460/000120919120045142/0001209191-20-045142-index.htm
2020-08-05Anish SuriPresident and CSOSell800.0020.0116,008.0034,558.00https://www.sec.gov/Archives/edgar/data/1645460/000120919120045698/0001209191-20-045698-index.htm
2020-08-04Anish SuriPresident and CSOBuy400.006.422,568.0034,958.00https://www.sec.gov/Archives/edgar/data/1645460/000120919120045142/0001209191-20-045142-index.htm
2019-11-01Anish SuriPresident and CSOBuy33,333.0035,333.00https://www.sec.gov/Archives/edgar/data/1645460/000120919119054991/0001209191-19-054991-index.htm
2020-08-05Anish SuriPresident and CSOBuy800.006.425,136.0035,358.00https://www.sec.gov/Archives/edgar/data/1645460/000120919120045698/0001209191-20-045698-index.htm
2020-08-03Anish SuriPresident and CSOBuy2,000.008.2616,520.0036,558.00https://www.sec.gov/Archives/edgar/data/1645460/000120919120045142/0001209191-20-045142-index.htm
2020-03-31Anish SuriPresident and CSOBuy16,666.0039,912.00https://www.sec.gov/Archives/edgar/data/1645460/000120919120024164/0001209191-20-024164-index.htm
2020-08-03Anish SuriPresident and CSOBuy3,800.006.4224,396.0040,358.00https://www.sec.gov/Archives/edgar/data/1645460/000120919120045142/0001209191-20-045142-index.htm
2018-08-16DANIEL R PASSERICEO and PresidentBuy6,000.008.0948,510.0047,600.00https://www.sec.gov/Archives/edgar/data/1645460/000120919118047605/0001209191-18-047605-index.htm
2018-12-27ANTHONY DIGIANDOMENICODirectorBuy20,000.004.7795,400.0050,000.00https://www.sec.gov/Archives/edgar/data/1645460/000120919118064233/0001209191-18-064233-index.htm
2019-06-06DANIEL R PASSERICEO and PresidentBuy3,000.006.9020,700.0050,600.00https://www.sec.gov/Archives/edgar/data/1645460/000120919119035525/0001209191-19-035525-index.htm
2018-12-21CHRISTOPHER A MARLETTDirectorBuy17,200.004.5377,916.0051,434.00https://www.sec.gov/Archives/edgar/data/1645460/000120919118064086/0001209191-18-064086-index.htm
2019-06-21DANIEL R PASSERICEO and PresidentBuy1,377.007.269,997.0251,977.00https://www.sec.gov/Archives/edgar/data/1645460/000120919119038900/0001209191-19-038900-index.htm
2018-12-28ANTHONY DIGIANDOMENICODirectorBuy7,000.004.6232,340.0057,000.00https://www.sec.gov/Archives/edgar/data/1645460/000120919119000261/0001209191-19-000261-index.htm
2020-09-29Cameron GrayDirectorBuy5,000.0015.0075,000.00672,500.00https://www.sec.gov/Archives/edgar/data/1645460/000089924320026662/0000899243-20-026662-index.htm
2020-09-30Cameron GrayDirectorBuy5,000.0015.3076,500.00677,500.00https://www.sec.gov/Archives/edgar/data/1645460/000089924320026662/0000899243-20-026662-index.htm
2020-10-03Anish SuriPresident and CSOBuy33,333.0067,891.00https://www.sec.gov/Archives/edgar/data/1645460/000089924320027608/0000899243-20-027608-index.htm
2018-12-26CHRISTOPHER A MARLETTDirectorBuy19,647.004.2984,285.6371,081.00https://www.sec.gov/Archives/edgar/data/1645460/000120919118064186/0001209191-18-064186-index.htm
2018-12-11CHRISTOPHER A MARLETTDirectorBuy7,543.004.8636,658.987,543.00https://www.sec.gov/Archives/edgar/data/1645460/000120919118062294/0001209191-18-062294-index.htm
2020-08-21Kerri-Ann MillarCFOBuy6,666.007,666.00https://www.sec.gov/Archives/edgar/data/1645460/000120919120048212/0001209191-20-048212-index.htm
2019-12-31CHRISTOPHER A MARLETTDirectorSell6,700.0015.77105,659.00768,503.00https://www.sec.gov/Archives/edgar/data/1645460/000120919119062325/0001209191-19-062325-index.htm
2019-12-27CHRISTOPHER A MARLETTDirectorSell9,000.0017.24155,160.00775,203.00https://www.sec.gov/Archives/edgar/data/1645460/000120919119062325/0001209191-19-062325-index.htm
2019-12-26CHRISTOPHER A MARLETTDirectorSell19,647.0017.53344,411.91784,203.00https://www.sec.gov/Archives/edgar/data/1645460/000120919119062031/0001209191-19-062031-index.htm
2019-12-23CHRISTOPHER A MARLETTDirectorSell17,000.0016.82285,940.00803,850.00https://www.sec.gov/Archives/edgar/data/1645460/000120919119062031/0001209191-19-062031-index.htm
2019-12-19CHRISTOPHER A MARLETTDirectorSell4,000.0017.0068,000.00820,850.00https://www.sec.gov/Archives/edgar/data/1645460/000120919119061377/0001209191-19-061377-index.htm
2019-12-17CHRISTOPHER A MARLETTDirectorSell20,732.0015.73326,114.36824,850.00https://www.sec.gov/Archives/edgar/data/1645460/000120919119061377/0001209191-19-061377-index.htm
2018-12-31CHRISTOPHER A MARLETTDirectorBuy18,521.004.6485,937.4489,602.00https://www.sec.gov/Archives/edgar/data/1645460/000120919119000270/0001209191-19-000270-index.htm
2018-12-12CHRISTOPHER A MARLETTDirectorBuy9,000.005.0945,810.009,000.00https://www.sec.gov/Archives/edgar/data/1645460/000120919118062473/0001209191-18-062473-index.htm